Heated Intraperitoneal Chemotherapy in Appendiceal Cancer Treatment

Robin Cianos, RN, OCN®, Sharon LaFever, MS, RN, AOCN®, and Nicole Mills, BSN, RN

Appendiceal cancer is rare and has been treated traditionally with repeated surgical debulking; however, cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) is becoming the preferred treatment modality because of improved survival. Nurses are responsible for knowing how to care for patients who are receiving or have received this treatment and need to be prepared to provide education on oncofertility. This case study illustrates the nursing implications of pregnancy and childbirth following CRS with HIPEC.

Cytoreductive Surgery

Staging is challenging because several histologic subtypes exist, with different survival outcomes. The subtypes and five-year disease-free survival rates are malignant carcinoid (93%), goblet cell carcinoid (81%), mucinous adenocarcinoma (58%), colonic-type adenocarcinoma (55%), and signet ring cell type (27%) (Turaga, Papas, & Gamblin, 2012). Tumors with mucinous histology are the most prevalent and are further categorized into low grade (pseudomyxoma peritonei syndrome [PMP] is the most common) and high grade. Low-grade tumors do not require systemic chemotherapy but are most often treated with CRS and HIPEC. High-grade tumors, depending on histology, often require systemic chemotherapy before and after CRS and HIPEC; in the authors' practice, that process often is described to patients as a “sandwich approach.”